Stem Cells Spin (WAR:SCS) Scaled Net Operating Assets: 0.66 (As of Mar. 2026)


WAR:SCS Stem Cells Spin SA WAR:SCS
25 GF Score
Price zł0.40
GF Value zł0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Stem Cells Spin Scaled Net Operating Assets?

Stem Cells Spin WAR:SCS 25 Scaled Net Operating Assets is 0.66 as of Mar. 2026. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Stem Cells Spin's operating assets for the quarter that ended in Mar. 2026 was zł9.13 Mil. Stem Cells Spin's operating liabilities for the quarter that ended in Mar. 2026 was zł2.77 Mil. Stem Cells Spin's Total Assets for the quarter that ended in Dec. 2025 was zł9.58 Mil. Therefore, Stem Cells Spin's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.66.


Stem Cells Spin Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Stem Cells Spin's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Cells Spin Scaled Net Operating Assets Chart

Stem Cells Spin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.46 0.50 0.51 0.59

Stem Cells Spin Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.62 0.65 0.66 0.66

WAR:SCS vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Stem Cells Spin's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stem Cells Spin Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's Scaled Net Operating Assets falls into.


WAR:SCS
25GF Score
Stem Cells Spin SA WAR:SCS
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stem Cells Spin Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Stem Cells Spin's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(9.498-2.959)/11.023
=0.59

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.575 - 0.077
=9.498

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.194 - 0.073 - 0.162
=2.959

Stem Cells Spin's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(9.128-2.774)/9.575
=0.66

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.15 - 0.022
=9.128

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.936 - 0 - 0.162
=2.774

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.66 mean?
Stem Cells Spin (WAR:SCS) has a Scaled Net Operating Assets of 0.66 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Stem Cells Spin and its competitors.
Is Stem Cells Spin's Scaled Net Operating Assets too high?
Stem Cells Spin's current Scaled Net Operating Assets is 0.66. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Scaled Net Operating Assets compare to VRTX and REGN?
Stem Cells Spin's Scaled Net Operating Assets of 0.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Stem Cells Spin and its competitors. Stem Cells Spin's current Scaled Net Operating Assets is 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current Scaled Net Operating Assets is 0.66. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Scaled Net Operating Assets is 0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?

Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued. The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10. GuruFocus considers Stem Cells Spin to be Significantly Overvalued.

Key valuation signals for WAR:SCS:

  • Scaled Net Operating Assets: 0.66
  • GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stem Cells Spin Business Description

Address Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score

Get the complete analysis for WAR:SCS

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.40
Price
zł0.10
GF Value